Research programme: Ras/Raf kinase inhibitors - Institute of Cancer Research/Royal Marsden Foundation

Drug Profile

Research programme: Ras/Raf kinase inhibitors - Institute of Cancer Research/Royal Marsden Foundation

Alternative Names: panRAF kinase inhibitors - The Institute of Cancer Research/Basilea; Ras/Raf pathway inhibitors - ICR

Latest Information Update: 30 Nov 2011

Price : $50

At a glance

  • Originator The Institute of Cancer Research
  • Class Small molecules
  • Mechanism of Action Proto oncogene protein b raf inhibitors; Proto oncogene proteins c raf inhibitors; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Malignant melanoma

Most Recent Events

  • 30 Nov 2011 Preclinical development is ongoing in United Kingdom
  • 22 Nov 2007 Preclinical trials in Malignant melanoma in United Kingdom (unspecified route)
  • 22 Nov 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top